SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

DIETZ, Vance et al. The laboratory confirmation of suspected measles cases in settings of low measles transmission: conclusions from the experience in the Americas. Bull World Health Organ [online]. 2004, vol.82, n.11, pp.852-857. ISSN 0042-9686.

    1. Pan American Health Organization. Elimination of measles in the Americas. XXIV Meeting of the Pan American Sanitary Conference. Washington (DC): Pan American Health Organization; 1995. [ Links ]

    2. de Quadros CA, Olive JM, Hersh BS, Strassburg M, Henderson DA, Brandling-Bennett D, et al. Measles elimination in the Americas – evolving strategies. JAMA 1996;275:224-9. [ Links ]

    3. Pan American Health Organization. Area of Family and Community Health, Immunization Unit. Public. Absence of transmission of the D9 measles virus in the region of the Americas, November 2002 – May 2003. Morbidity and Mortality Weekly Report 2003;52:228-9. [ Links ]

    4. Venczel L, Rota J, Dietz V, Morris-Glasgow V, Siqueira M, Quiroga E, et al. The measles laboratory network in the Region of the Americas. Journal of Infectious Diseases 2003;187 Suppl 1:S140-5. [ Links ]

    5. Onzanne GD, Halewyn MA. Performance and reliability of the Enzygnost measles enzyme-linked immuno-sorbent assay for detection of measles virus-specific immunoglobulin M antibody during a large measles epidemic. Journal of Clinical Microbiology 1992;30:564-9. [ Links ]

    6. Thomas HIJ, Barrett E, Hesketh LM, Wynne A, Morgan-Capner P. Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella infection. Journal of Clinical Virology 1999;14:107-18. [ Links ]

    7. Ratnam S, Tipples G, Head C, Fauvel M, Earon M, Ward B. Performance of indirect immunoglobulin M (IgM) serology tests and IgM capture assays for laboratory diagnosis of measles. Journal of Clinical Microbiology 2000;38:99-104. [ Links ]

    8. Mausner JS, Kramer S. Screening in the detection of disease. In: Epidemiology – an introductory text. Philadelphia: WB Saunders; 1985: Chapter 9. [ Links ]

    9. Centers for Disease Control. Measles. In: Atkinson W, Wolfe C, editors. Epidemiology and prevention of vaccine-preventable diseases. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control; 2002:Chapter 9. [ Links ]

    10. Pan American Health Organization. Measles case classification. Frequent dilemmas in the field. EPI Newsletter 2001;23:4-5. [ Links ]

    11. Pan American Health Organization. Measles case classification. II. Frequent dilemmas in the field. EPI Newsletter 2001;23:3-4. [ Links ]

    12. Helfand RF, Chibi T, Biellik R, Shearley A, Bellini WJ. Negative impact of clinical misdiagnosis of measles on health worker's confidence in measles vaccine. Epidemiology and Infection 2003;132:7-10. [ Links ]

    13. Ballew HC. Neutralization. In: Spector S, Hodinka RL, Young SA, editors. Clinical virology manual, 3rd ed. Washington (DC): ASM Press; 2000:127-39. [ Links ]

    14. Jenkin GA, Chibo D, Kelly HA, Lynch P, Catton M. What is the cause of a rash after measles-mumps-rubella vaccination? Medical Journal of Australia 1999;171:194-5. [ Links ]

    15. Enders G. Serologic test combinations for safe detection of rubella infections. Reviews of Infectious Diseases 1985;7:S113-22. [ Links ]

    16. Banatvala JE, Best JM. Rubella. In: Collier L, Balows A, Sussman M, editors. Microbiology and microbial infections. New York: Oxford Press; 1998. [ Links ]

    17. Helfand RF, Heath JL, Anderson LJ , Maes E, Guris D, Bellini WJ. Diagnosis of measles with an IgM capture EIA: The optimal timing of specimen collection after rash onset. Journal of Infectious Diseases 1997;175:195-9. [ Links ]

    18. Helfand RF, Kebede S, Gary HE, Beyene H, Bellini WJ. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clinical and Diagnostic Laboratory Immunology 1999;6:178-80. [ Links ]

    19. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 2000;105:E62. Available from:URL: [ Links ]

    20. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: A double-blind placebo controlled trial in twins. Lancet 1986;26:939-42. [ Links ]

    21. Christenson B, Bottiger M, Heller L. Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden : first experience. BMJ 1983;287:389-91. [ Links ]

    22. Freeman TR, Stewart MA, Turner L. Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal 1993;149:1669-74. [ Links ]

    23. Edees S, Pullan CR, Hull D. A randomized single blind trial of a combined Mumps Measles Rubella vaccine to evaluate serological response and reactions in the UK population. Public Health 1991;105:91-7. [ Links ]

    24. de Quadros CA, Izurieta H, Carrasco P, Brana M, Tambini G. Progress toward measles eradication in the Region of the Americas. Journal of Infectious Diseases 2003;187 Suppl 1:S102-10. [ Links ]

    25. Cutts FT, Brown DW. The contribution of field tests to measles surveillance and control: A review of available methods. Reviews of Medical Virology 1995;5:35-40. [ Links ]